Comox's Aurora Cannabis Inc., has announced the company鈥檚 discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora鈥檚 breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year. 

鈥淭his discovery offers a critical solution to a pressing challenge in the cannabis industry worldwide. At Aurora Coast, our state-of-the-art research and development facility, we  continuously search for ways to add value to our proprietary cannabis cultivars, and this discovery will lead to new means of managing disease in cannabis production. This success story  underscores the impact of our investment in scientific excellence, a commitment that sets Aurora apart from our competitors,鈥� says Lana Culley, Vice President of Innovation and International Operations at Aurora. 

The discovery of PM2 will further the company鈥檚 mission to enhance the biosecurity of production facilities, reduce production costs, and improve product quality. 

As a global medical cannabis company enabled by science, Aurora's dedication to scientific research and innovation has led to remarkable advancements, notably boosting potency and yield. These improvements have overall reduced costs and increased efficiency. This cutting edge genetic research aims to surpass traditional breeding limitations, leading to advanced cultivation methods and new market opportunities worldwide.